Advanced search
Publication Cover
OncoTargets and Therapy Volume 10, 2017 - Issue
Submit an article Journal homepage
65
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Prognosis of prostate cancer with initial prostate-specific antigen >1,000 ng/mL at diagnosis

Hung-Cheng Kan1 Department of Urology, Chang Gung Memorial Hospital
,
Chen-Pang Hou1 Department of Urology, Chang Gung Memorial Hospital;2 School of Medicine, Chang Gung University, Taoyuan, Taiwan, Republic of China
,
Yu-Hsiang Lin1 Department of Urology, Chang Gung Memorial Hospital;2 School of Medicine, Chang Gung University, Taoyuan, Taiwan, Republic of China
,
Ke-Hung Tsui1 Department of Urology, Chang Gung Memorial Hospital;2 School of Medicine, Chang Gung University, Taoyuan, Taiwan, Republic of China
,
Phei-Lang Chang1 Department of Urology, Chang Gung Memorial Hospital;2 School of Medicine, Chang Gung University, Taoyuan, Taiwan, Republic of China
&
Chien-Lun Chen1 Department of Urology, Chang Gung Memorial Hospital;2 School of Medicine, Chang Gung University, Taoyuan, Taiwan, Republic of ChinaCorrespondence[email protected]
Pages 2943-2949 | Published online: 12 Jun 2017

References

  • IlicDNeubergerMMDjulbegovicMDahmPScreening for prostate cancerCochrane Database Syst Rev20131CD004720
  • EdgeSBByrdDRComptonCCFritzAGGreeneFLTrottiAAmerican Joint Committee on Cancer Staging Manual7th edNew YorkSpringer2010
  • WangMCValenzuelaLAMurphyGPChuTMPurification of a human prostate specific antigenInvest Urol197917215916389106
  • StameyTAYangNHayARMcNealJEFreihaFSRedwineEProstate-specific antigen as a serum marker for adenocarcinoma of the prostateN Engl J Med1987317159099162442609
  • WalterLCBertenthalDLindquistKKonetyBRPSA screening among elderly men with limited life expectanciesJAMA2006296192336234217105796
  • ItoKProstate cancer in Asian menNat Rev Urol201411419721224595118
  • NCCN guideline PCaNational Comprehensive Cancer Network “NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Prostate Cancer Version 2.2014”Fort Washington, PA20132014
  • MahalBAAizerAAEfstathiouJANguyenPLAssociation of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancerCancer20161221788326371600
  • BrandtJGarneJPTengrupIManjerJAge at diagnosis in relation to survival following breast cancer: a cohort studyWorld J Surg Oncol20151313325889186
  • BechisSKCarrollPRCooperbergMRImpact of age at diagnosis on prostate cancer treatment and survivalJ Clin Oncol201129223524121135285
  • HugginsCHodgesCVStudies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941J Urol2002168191212050481
  • HarrisWPMostaghelEANelsonPSMontgomeryBAndrogen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletionNat Clin Pract Urol200962768519198621
  • KaisaryAVTyrrellCJPeelingWBGriffithsKComparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinomaBr J Urol19916755025081828183
  • VogelzangNJChodakGWSolowayMSGoserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study GroupUrology19954622202267624991
  • SunMChoueiriTKHamnvikOPComparison of gonadotropin-releasing hormone agonists and orchiectomy: effects of androgen-deprivation therapyJAMA Oncol20162450050726720632
  • OefeleinMGFengAScolieriMJRicchiuttiDResnickMIReassessment of the definition of castrate levels of testosterone: implications for clinical decision makingUrology20005661021102411113751
  • MercaderMSenguptaSBodnerBKEarly effects of pharmacological androgen deprivation in human prostate cancerBJU Int2007991606717227493
  • MontironiRMagi-GalluzziCMuzzonigroGPreteEPolitoMFabrisGEffects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinomaJ Clin Pathol199447109069137525657
  • MoroteJEsquenaSAbascalJMFailure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancerUrol Int200677213513816888418
  • MoroteJOrsolaAPlanasJRedefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapyJ Urol20071784 Pt 11290129517698136
  • OefeleinMGCornumRFailure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithmJ Urol20001643 Pt 172672910953134
  • SasakiTOnishiTHoshinaANadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasisProstate Cancer Prostatic Dis201114324825221502970
  • TomiokaATanakaNYoshikawaMNadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancerBMC Urol20141413324773608
  • CeresoliGLDe VincenzoFSautaMGBonomiMZucaliPARole of chemotherapy in combination with hormonal therapy in first-line treatment of metastatic hormone-sensitive prostate cancerQ J Nucl Med Mol Imaging201559437438026222275
  • MillerRESweeneyCJChemotherapy for metastatic castrate-sensitive prostate cancerProstate Cancer and Prostatic Dis2016192139144

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.